Drug intelligence / Profile preview

CJ-16118

Development stage: Unknown
Lead developer: CJ CheilJedang
Modality: Small Molecules
Administration: Oral

Overview

CJ-16118 is the major active metabolite of CJ-15314, an investigational pharmaceutical compound. CJ-15314—and by extension, CJ-16118—appears to be under clinical evaluation for safety, pharmacokinetics, and pharmacodynamics in healthy subjects. Details on its exact mechanism of action, molecular target, or specific clinical indication are not explicitly provided in public sources. Its evaluation as a metabolite in a clinical study indicates its relevance to pharmacological activity and possible therapeutic application[3].

Beyond the preview

Go deeper on CJ-16118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-16118.

Explore the full profile